Avanos Medical (NYSE:AVNS) SVP Kerr Holbrook Sells 15,000 Shares

Avanos Medical, Inc. (NYSE:AVNS) SVP Kerr Holbrook sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total value of $165,000.00. Following the sale, the senior vice president owned 83,860 shares of the company’s stock, valued at $922,460. This trade represents a 15.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Avanos Medical Stock Down 0.2%

AVNS stock traded down $0.03 on Wednesday, hitting $11.22. 336,724 shares of the company’s stock were exchanged, compared to its average volume of 542,336. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.38. The stock has a market cap of $520.60 million, a P/E ratio of -1.10 and a beta of 1.19. The firm has a 50 day moving average price of $11.56 and a two-hundred day moving average price of $11.85. Avanos Medical, Inc. has a 12-month low of $9.30 and a 12-month high of $19.91.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.10. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The business had revenue of $177.80 million for the quarter, compared to the consensus estimate of $164.50 million. During the same quarter in the previous year, the business earned $0.33 EPS. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. As a group, equities research analysts expect that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Tuesday, October 14th. Zacks Research upgraded Avanos Medical to a “hold” rating in a research report on Tuesday, August 12th. Finally, Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce”.

Institutional Trading of Avanos Medical

A number of institutional investors have recently bought and sold shares of AVNS. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Avanos Medical during the second quarter worth about $192,000. T. Rowe Price Investment Management Inc. grew its stake in Avanos Medical by 24.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company’s stock valued at $53,847,000 after purchasing an additional 746,264 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Avanos Medical during the 2nd quarter valued at approximately $262,000. Nuveen LLC acquired a new stake in shares of Avanos Medical during the first quarter worth approximately $1,839,000. Finally, Strs Ohio bought a new stake in shares of Avanos Medical in the first quarter worth $460,000. 95.17% of the stock is owned by hedge funds and other institutional investors.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.